The estimated Net Worth of Kazuko Matsuda is at least $2.97 Milion dollars as of 23 August 2021. Kazuko Matsuda owns over 60,000 units of Medicinova Inc stock worth over $633,072 and over the last 13 years he sold MNOV stock worth over $0. In addition, he makes $2,336,780 as Chief Medical Officer i Director at Medicinova Inc.
Sign up
Kazuko Matsuda MNOV stock SEC Form 4 insiders trading
Kazuko has made over 6 trades of the Medicinova Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of MNOV stock worth $138,000 on 23 August 2021.
The largest trade he's ever made was exercising 102,804 units of Medicinova Inc stock on 24 June 2021 worth over $257,010. On average, Kazuko trades about 10,880 units every 35 days since 2011. As of 23 August 2021 he still owns at least 322,996 units of Medicinova Inc stock.
You can see the complete history of Kazuko Matsuda stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kazuko Matsuda biography
Dr. Kazuko Matsuda M.D. Ph.D. serves as Chief Medical Officer, Director of the Company. Dr. Matsuda served as our Vice President of Clinical Development from April 2010 to September 2011. Dr. Matsuda has responsibility for all of our clinical development. From August 2008 to November 2009, Dr. Matsuda served as an assistant professor with the University of Southern California, Keck School of Medicine. From August 2005 to July 2008, Dr. Matsuda served as Clinical Fellow with the Children’s Hospital Los Angeles. Dr. Matsuda commenced her residency in internal medicine/pediatrics at Michigan State University and completed a pediatric residency at Loma Linda University. Dr. Matsuda is a board-certified pediatrician in both the United States and Japan. Dr. Matsuda holds an M.D. and Ph.D. from Sapporo Medical University School of Medicine and an MPH from Harvard University, School of Public Health.
What is the salary of Kazuko Matsuda?
As the Chief Medical Officer i Director of Medicinova Inc, the total compensation of Kazuko Matsuda at Medicinova Inc is $2,336,780. There are 1 executives at Medicinova Inc getting paid more, with Yuichi Iwaki having the highest compensation of $3,761,890.
How old is Kazuko Matsuda?
Kazuko Matsuda is 54, he's been the Chief Medical Officer i Director of Medicinova Inc since 2019. There are 7 older and 3 younger executives at Medicinova Inc. The oldest executive at Medicinova Inc is Dr. Yuichi Iwaki M.D., Ph.D., 71, who is the Co-Founder, Pres, CEO & Exec. Director.
What's Kazuko Matsuda's mailing address?
Kazuko's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037.
Insiders trading at Medicinova Inc
Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima oraz Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.
What does Medicinova Inc's logo look like?
Complete history of Kazuko Matsuda stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director